A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)

September 30, 2019
https://clinicaltrials.gov/ct2/show/NCT03834506
Cancer - Prostate
Principal Investigator: Clara Hwang, MD

MK-3475-921

Pembrolizumab

Castration-Resistant

Docetaxel

KEYNOTE-921

Open